Moderna loses a Bayh–Dole shield in Northwestern’s vaccine patent case

The story

A federal judge has rejected Moderna’s attempt to use the U.S. government’s license to federally funded university inventions as a direct shield against Northwestern University’s vaccine-patent claims. The September 30 opinion narrows Moderna’s defenses, but it does not determine that the company infringed any patent or owes damages. The core questions of claim scope, validity and infringement remain in discovery.

Northwestern’s case, filed in Delaware in 2024, asserts three patents: U.S. Patent Nos. 9,216,155, 10,328,026 and 8,323,686. The patents concern synthetic nanostructures associated with transporting nucleic acids and other molecules. Northwestern accuses Moderna’s Spikevax COVID-19 vaccine and mResvia RSV vaccine of using the claimed technology; its briefing also identifies mNexspike. Moderna disputes the allegations.

The contested defense arose from the Bayh–Dole Act, the 1980 law that lets universities, small businesses and other contractors retain patent rights in inventions developed with federal funding, subject to statutory obligations. Among them is a nonexclusive, irrevocable, paid-up U.S. government license to practice—or have practiced on its behalf—the funded invention. Moderna argued that this government license authorized its manufacture and sale of Spikevax doses procured through federal contracts.

U.S. District Judge J. Campbell Barker rejected that reading. His opinion says the Bayh–Dole license belongs to the government, is nontransferable and does not provide a private contractor with its own cause of action or affirmative defense. The court dismissed with prejudice Moderna’s counterclaims for a declaration based on the government license and for breach of contract. It also struck defenses based on that theory, including license, third-party-beneficiary status, patent exhaustion and unclean hands.

The distinction matters because Congress created a separate route for suppliers working for the government. Under 28 U.S.C. § 1498(a), when a patented invention is used or manufactured for the United States with its authorization or consent, the patent owner’s remedy can shift to a compensation action against the government in the U.S. Court of Federal Claims. The Delaware court concluded that treating Bayh–Dole’s government license as a parallel contractor defense would let suppliers bypass Section 1498’s specific conditions and remedy.

Moderna has not lost that separate Section 1498 argument. The judge denied Northwestern’s challenge to it without prejudice, allowing the parties to return after the U.S. Court of Appeals for the Federal Circuit rules in Arbutus Biopharma v. Moderna, a related dispute over when COVID-19 vaccine production and distribution count as work for the government. The court therefore resolved one legal theory while expressly leaving the government-contract question open.

The scale is substantial. The parties stipulated that 500,001,540 Spikevax doses were sold under federal contract C0100. Of those, 6,244,340 were administered to U.S. government employees, and Northwestern has agreed not to seek damages from Moderna for that subset. The treatment of the remaining doses depends on the unresolved Section 1498 analysis as well as the underlying patent merits.

The patents themselves also remain contested. Patent records identify Northwestern as the assignee and show a confirmatory license to the National Institutes of Health for the ’155 patent. A recorded government interest supports the existence of federal rights; it does not, by itself, prove that Moderna’s products practice every limitation of the asserted claims. Nor does this procedural ruling establish that the claims are valid over prior art.

INNOVOX analysis: the decision clarifies a commercialization rule with implications beyond vaccines. Public funding often sits upstream of private products in biotechnology, semiconductors, energy and advanced materials. A supplier cannot assume that the government’s retained Bayh–Dole license travels automatically with a procurement contract. The practical protection may instead turn on contract language, government authorization and the fact-specific test under Section 1498.

That separation preserves Bayh–Dole’s basic bargain: research institutions can commercialize patents developed with federal support while the government retains rights for public purposes. It also places responsibility on companies to identify the legal route that actually covers their work. What to watch now is the Federal Circuit’s Arbutus decision, followed by the Delaware court’s treatment of the remaining defense and the technical evidence on Northwestern’s three patents.

INNOVOX analysis

The decision draws an important boundary around federally funded inventions. A government research license is not a transferable immunity card for every commercial supplier. Companies seeking protection for work performed for the United States must satisfy the separate conditions of Section 1498, while universities retain enforceable patent rights outside that channel. That distinction can influence pricing, contracting and freedom-to-operate analysis wherever public funding and private manufacturing meet.

What to watch

Watch the Federal Circuit’s pending Arbutus appeal, which will shape the unresolved Section 1498 issue, and the parties’ claim-construction and validity positions on Northwestern’s patents. Also watch whether Moderna appeals the Bayh–Dole ruling after final judgment or pursues a license or settlement before the court reaches infringement and damages.